On May 4 President and CEO Rami Levin was interviewed by Eugenie Hsu of The Raymond A. Wood Foundation about Saniona and the recent positive phase 2 results of Tesomet in Hypothalamic Obesity.
On April 28 Saniona held an Investor Call on the positive topline results from the phase 2 trial with Tesomet in Hypothalamic Obesity. The event featured a presentation by Key Opinion Leader and Principal Investigator on the phase 2 trial of Tesomet in Hypothalamic Obesity Professor Ulla Feldt-Rasmussen, M.D. DMSc (Department of Medical Endocrinology and Metabolism, Rigshospitalet, Copenhagen University Hospital) who discussed the current treatment landscape and unmet medical need for patients with Hypothalamic Obesity.
On April 23 Saniona (represented by Rami Levin, President and CEO, Jørgen Drejer, CSO, and Dean Carson, VP Medical Affairs) gave a company presentation at the "BMO Hidden Gems in Healthcare" conference call series.